<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>新的人类基因编辑试验有希望的开端 A promising start to new human gene-editing trials</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">A promising start to new human gene-editing trials<br/>新的人类基因编辑试验有希望的开端 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-12-09 20:42:04</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2020/12/02e09e719ea4528c877779309703b663.jpg"><img src="http://img2.diglog.com/img/2020/12/02e09e719ea4528c877779309703b663.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>Gene therapy has had a long and sometimes difficult history. Plenty of human genetic disorders can be traced to problems with a single gene, and that makes them a tempting target for correction. But  someone died in a very early gene-therapy trial, which set the entire field back considerably. And, despite a far more cautious approach, the risks are still considerable, as two deaths during a trial  occurred just this year.</p><p>基因疗法已有悠久的历史，有时甚至是艰难的历史。大量的人类遗传疾病可以追溯到单个基因的问题，这使其成为诱人的纠正目标。但是有人在一个非常早期的基因疗法试验中死亡，这使整个研究领域大为改观。而且，尽管采取了更为谨慎的方法，但风险仍然很大，因为今年试验期间发生了两人死亡。</p><p> But for researchers in the field, and those suffering from genetic diseases, this week provides some hope that the field&#39;s long-delayed promise might eventually be met. At a virtual scientific conference, a group presented the results of a large safety trial that saw 50 of 52 patients able to discontinue treatments for hemophilia. And a separate paper describes the use of CRISPR gene-editing and a blood stem cell transplant to successfully treat patients with sickle cell anemia or a related disorder.</p><p> 但是对于本领域的研究人员以及那些患有遗传疾病的研究人员而言，本周给他们带来了希望，即该领域长期以来的长期希望最终将得以实现。在一个虚拟的科学会议上，一个小组介绍了一项大型安全性试验的结果，该试验发现52名患者中有50名能够中止血友病治疗。另一篇论文描述了使用CRISPR基因编辑和血液干细胞移植成功治疗镰状细胞性贫血或相关疾病的患者。</p><p>  The hemophilia trial was typical of most early efforts at gene therapy. In this case, the disease is caused by a defect in a single gene, so providing cells with a new copy will correct the problem. And, since the protein that&#39;s encoded by that gene circulates in the blood, you don&#39;t have to target a small and potentially difficult-to-access population of cells in order to correct things—targeting a new copy of the gene to any cells that can export proteins to the bloodstream will work.</p><p>  血友病试验是基因治疗中大多数早期工作的典型代表。在这种情况下，疾病是由单个基因的缺陷引起的，因此为细胞提供新的拷贝将纠正该问题。而且，由于该基因编码的蛋白质在血液中循环，因此您不必针对一小部分且可能难以接近的细胞群体进行校正，就可以针对新的副本该基因对任何能够将蛋白质输出到血液中的细胞都是有效的。</p><p> In this case, the defective gene produces a protein called factor IX, which is part of the cascade that enables clotting. People with a defective factor IX gene can receive infusions of a purified version, but they have to be repeated every other week and are quite expensive. Gene therapy promises to eliminate the need for them. The method used in the new trial involves using a virus carrying the factor IX gene to infect liver cells. The virus integrates into the infected cells&#39; genome, providing them with a permanent copy of a functional factor IX gene.</p><p> 在这种情况下，缺陷基因会产生一种称为因子IX的蛋白质，该蛋白质是级联的一部分，可以进行凝血。 IX因子基因缺陷的人可以接受纯化形式的输注，但必须每两周重复一次，而且价格昂贵。基因疗法有望消除对它们的需求。新试验中使用的方法涉及使用携带因子IX基因的病毒感染肝细胞。该病毒会整合到受感染的细胞中。基因组，为他们提供功能性IX基因的永久拷贝。</p><p> According to  a summary of the meeting presentation, the phase III trial enrolled 52 patients, and 50 of them completed the therapy. By six months after an infusion of the virus, these patients&#39; levels of factor IX had risen to the point where they had a bleeding risk similar to the low end of the general population. That level is classified as a very mild hemophilia and doesn&#39;t require treatment. The side effects mostly involved an immune response to the virus, which was treated with steroids.</p><p> 根据会议摘要，III期试验招募了52位患者，其中50位完成了治疗。在输注病毒后六个月，这些患者IX因子的水平已经上升到他们具有与普通人群低端相似的出血风险的程度。该水平被分类为非常轻度的血友病，不需要治疗。副作用主要涉及对病毒的免疫反应，该病毒用类固醇治疗。</p><p>    Both of the patients who didn&#39;t respond to the treatment also had immune issues due to prior exposure to the virus used to insert the replacement gene. In one, the virus triggered a strong immune response during transfusion of the virus, which had to be discontinued. The second had very high levels of antibodies that neutralized the virus. But 40 percent of the other patients also had prior exposures to the virus, and this didn&#39;t pose problems during the trial.</p><p>    由于事先暴露于用于插入替代基因的病毒中，因此对治疗没有反应的两名患者都存在免疫问题。在其中一种情况下，该病毒在输血期间引发了强烈的免疫反应，必须停止免疫。第二种具有很高水平的中和病毒的抗体。但是，其他患者中有40％也曾接触过该病毒，这在试验期间没有造成问题。</p><p>  The second trial of gene therapy was substantially smaller, and the therapy was far more complex. It focused on two types of anemia where the underlying mutations provide some protection from malaria: sickle cell anemia and a form of β-thalassemia. These alter the function of red blood cells and cause severe health issues. β-thalassemia damages one of the genes for hemoglobin, resulting in a severe underproduction; people with sickle cell disease produce a hemoglobin that forms polymers, resulting in misshapen red blood cells.</p><p>  基因疗法的第二次试验要小得多，而且疗法要复杂得多。它着重于两种类型的贫血，其中潜在的突变为疟疾提供了一定的保护：镰状细胞性贫血和一种β-地中海贫血。这些改变红细胞的功能并引起严重的健康问题。 β地中海贫血会破坏血红蛋白的一种基因，导致严重的生产不足；镰状细胞病患者产生的血红蛋白会形成聚合物，导致畸形的红细胞。 </p><p> While it&#39;s possible to treat β-thalassemia by a gene therapy similar to the one that worked for hemophilia—simply provide a replacement copy of the defective gene—that won&#39;t necessarily work for sickle cell anemia, which produces an altered form of hemoglobin. One of the ideas that&#39;s been considered for treating these anemias is to reactivate the fetal hemoglobin gene. This has a higher affinity for oxygen, allowing it to pick up oxygen from the adult form in the placenta. But it shuts off within a few years of birth.</p><p>尽管可以通过类似于血友病的基因疗法来治疗β地中海贫血，但只需提供缺陷基因的替代品即可，而这种疗法对镰状细胞性贫血不一定有效血红蛋白的变化形式。考虑治疗这些贫血的想法之一是重新激活胎儿血红蛋白基因。这对氧气具有更高的亲和力，使其能够从胎盘中的成年形式吸收氧气。但是它会在出生后的几年内关闭。</p><p> This shutdown is mediated in part by a protein called BCL11A. So, in theory, if you eliminate BCL11A, you can reactivate the fetal hemoglobin genes. Unfortunately, getting rid of it isn&#39;t simple, because it performs essential functions in other cells.</p><p> 这种关闭部分地由一种称为BCL11A的蛋白质介导。因此，从理论上讲，如果消除了BCL11A，则可以重新激活胎儿血红蛋白基因。不幸的是，摆脱它并不容易，因为它在其他单元中执行必不可少的功能。</p><p> To get around this problem, the researchers behind the new work obtained blood stem cells from patients with β-thalassemia and sickle cell disease. These were then subjected to CRISPR gene editing, which deleted a piece of DNA that was essential for activating BCL11A in red blood cells. It wasn&#39;t perfectly efficient, as you&#39;d expect, but it did reach levels where about 80 percent of the copies of BCL11A had the editing performed. And, when these edited stem cells formed red blood cells in culture, they produced elevated levels of fetal hemoglobin.</p><p> 为了解决这个问题，这项新工作的研究人员从β地中海贫血和镰状细胞病患者那里获得了血液干细胞。然后对它们进行CRISPR基因编辑，删除了对激活红细胞中BCL11A至关重要的DNA片段。正如您所期望的那样，它的效率不是很高，但是确实达到了可以编辑的BCL11A副本的80％的水平。而且，当这些经过编辑的干细胞在培养中形成红细胞时，它们产生的胎儿血红蛋白水平升高。</p><p> The actual clinical trial involved a risky procedure: the blood stem cells of two patients, one with β-thalassemia, one with sickle cell disease, were eliminated. The gene-edited stem cells were then infused, allowing the patients to develop a new blood supply using them. This is a very aggressive procedure and requires extensive medical support; both had severe events that required treatment during the recovery. A  profile of one of the trial&#39;s participants may help you explain why someone would risk it.</p><p> 实际的临床试验涉及危险的程序：淘汰了两名患者的血液干细胞，一名患有β地中海贫血，一名患有镰状细胞病。然后注入经过基因编辑的干细胞，使患者能够利用它们开发新的血液供应。这是一个非常激进的程序，需要广泛的医疗支持；双方都有严重的事件，需要在康复期间进行治疗。试用参与者之一的资料可以帮助您解释为什么有人会冒险。</p><p>     For both patients, it worked. For the ß-thalassemia patient, the levels of fetal hemoglobin were at about 30 miligrams per liter before the procedure, and gradually rose until reaching 1,300 grams per liter a year after. For the sickle cell patient, the fetal hemoglobin accounted for half her total a year after the procedure. The amount of sickle cell hemoglobin dropped accordingly. The latter patient had been averaging seven severe vascular events a year, over three of which typically required hospitalization. Since the procedure, she&#39;s only had three, all of which were arguably from its recovery period.</p><p>     对于两个患者，它都有效。对于β地中海贫血患者，在手术前胎儿血红蛋白的水平约为每升30毫克，并逐渐升高直至一年后达到每升1300克。对于镰状细胞患者，手术后一年，胎儿血红蛋白占总数的一半。镰状细胞血红蛋白的量相应下降。后者患者平均每年发生七次严重血管事件，其中三例通常需要住院。自该程序以来，她只有三个人，所有这些人都可以说是从恢复期开始的。</p><p> While only two patients had passed the year mark since the trial began, another eight patients had crossed the three month time point since receiving the same treatment. While the paper doesn&#39;t go into details, it indicates that the results are &#34;broadly consistent with the findings in the two patients described here.&#34;</p><p> 自试验开始以来，只有两名患者通过了年关，但自接受相同治疗以来，又有八名患者越过了三个月的时间点。尽管该论文没有进行详细介绍，但它表明结果与此处所述的两名患者的发现大体上一致。</p><p>  There are a number of reasons that this procedure doesn&#39;t completely switch patients over to fetal hemoglobin. For starters, the gene editing wasn&#39;t 100 percent efficient. But beyond that, its activity is regulated by factors other than the protein targeted here, and activating it doesn&#39;t shut down other forms of hemoglobin. This isn&#39;t an issue in ß-thalassemia, since the mutation just underproduces a normal hemoglobin. But it does mean that an altered form continues to be produced in sickle cell patients. The key factor is that there&#39;s enough of the normal form around to interfere with the formation of hemoglobin polymers.</p><p>  有很多原因导致该程序无法将患者完全转换为胎儿血红蛋白。对于初学者来说，基因编辑的效率不是100％。但除此之外，它的活性还受此处靶向的蛋白质以外的因素调节，激活它不会关闭其他形式的血红蛋白。这不是β地中海贫血的问题，因为这种突变只会产生正常的血红蛋白。但这确实意味着镰状细胞患者会继续产生改变的形式。关键因素是周围有足够多的正常形式干扰血红蛋白聚合物的形成。 </p><p> One of the big worries of CRISPR is that its editing isn&#39;t always directed to the correct sequence; there are sometimes &#34;off target&#34; edits. In this case, the researchers did tests designed to identify off-target edits using cultured cells, and didn&#39;t find any. That doesn&#39;t mean that a rare instance didn&#39;t end up in the ones put back into patients, but it does make it much less likely.</p><p>CRISPR的一大忧虑是它的编辑并非总是针对正确的序列。有时会＆＃34;偏离目标＆＃34;编辑。在这种情况下，研究人员进行了旨在通过培养细胞识别脱靶编辑的测试，但未发现任何结果。这并不意味着没有一个罕见的案例最终出现在被送回患者的案例中，但这确实使这种情况的可能性大大降低。</p><p> None of this is to say that this particular approach to gene therapy is going to see widespread use (although you can be the two companies behind it are hoping that&#39;s the case). For one, a number of other approaches have already been approved for testing and, in some cases, are already being used in patients. And all of them need a lot of additional safety and efficacy testing. And both procedures require enough medical attention that they will never be routine.</p><p> 这并不是说基因疗法的这种特殊方法将得到广泛使用（尽管您可能是背后的两家公司都希望如此）。一方面，许多其他方法已经被批准用于测试，并且在某些情况下已经在患者中使用。而且所有这些都需要大量其他安全性和功效测试。两种程序都需要足够的医疗护理，以至于它们永远不会成为常规。</p><p> But the results suggest that, after an extensive and necessary hiatus to help define and address safety issues, gene therapy is seeing some progress again. And, in the intervening years, biologists have developed a number of additional tools that have the potential to make it far more effective.</p><p> 但是结果表明，经过广泛而必要的中断以帮助定义和解决安全问题之后，基因治疗又有了新的进展。并且，在随后的几年中，生物学家开发了许多其他工具，有可能使它更加有效。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://arstechnica.com/science/2020/12/new-human-gene-therapy-trials-tackle-sickle-cell-hemophilia/">https://arstechnica.com/science/2020/12/new-human-gene-therapy-trials-tackle-sickle-cell-hemophilia/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/编辑/">#编辑</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/start/">#start</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/基因/">#基因</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>